Additional information received on 10dec2019 indicating that there was no delay in surgery noted and a replacement of the device was used to complete the procedure.It was reported that the patient's status was currently stable.The device was not returned for evaluation.The device history record were reviewed and did not reveal any anomaly that could explain the reported event.During the manufacturing process a leakage test is performed on 100% of the devices.Controls also include an occlusion test to verify the strength of the solvent bond joints (pull test) of the patient line and burette lines.In addition, at final release, a sampling of 5 units is tested for leakage conditions.The filter cap issues encountered at incoming inspection would not cause drained fluid to leak when the devices was used as intended.The instructions for use caution ¿do not overfill the cylinder.Keep the cylinder and the check valve upright at all times.¿ ¿do not tip drainage cylinder while inside of cylinder is wet.Do not allow cylinder filter to become wet¿.The review of integra complaint tracking database since 2016 reveals a leakage complaint rate of (b)(4) for eds products family (basis of (b)(4) devices shipped from manufacturing site).The complaint was verified as valid.Udi di: (b)(4).Between 05nov2019 and 30jun2020, approximately 2,200 mdrs submitted electronically by integra lifesciences via trackwise, integra's complaint handling system, were not received by cdrh due to a computer system issue.Within this time period, an error with integra's middleware, which facilitates communications between trackwise and the fda system, caused the complaint records to close and indicate we had received an acknowledgement 3 from the fda when we had not.Integra interpreted the acknowledgement as a successful submission; however, subsequent investigation revealed the acknowledgement 3 received was from our middleware and not from the fda (these acknowledgements have been retained as part of the documentation of the mdr).The malfunction was related to the relocation of the trackwise application to a new data center during the transition of integra's corporate headquarters from plainsboro, nj to princeton, nj.Previously, integra had been successfully receiving acknowledgements 1, 2, and 3 from the fda, and our records reflect these acknowledgements, including the date and time stamps.Capa pr (b)(4) and nc 20-011 have been opened by integra to further investigate the nonconformance and develop a corrective action plan.The middleware error has been corrected, and integra has filed mdrs since the correction and verified that the appropriate acknowledgements have been received from the fda.Integra is resubmitting all impacted mdr reports for the time period 05nov2019 through 30jun2020.Integra lifesciences contacted donna engleman, director of regulatory programs, office of product evaluation and quality and michelle rios, assistant director, mdr team, office of product evaluation and quality on july 8-9, 2020 to report these issues regarding mdr reports.
|